- Home
- CSL vs INCY Comparison
CSL vs INCY Comparison
Compare CSL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSL
- INCY
- Stock Information
- Founded
- CSL 1917
- INCY 1991
- Country
- CSL United States
- INCY United States
- Employees
- CSL N/A
- INCY N/A
- Industry
- CSL Specialty Chemicals
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CSL Industrials
- INCY Health Care
- Exchange
- CSL Nasdaq
- INCY Nasdaq
- Market Cap
- CSL 16.2B
- INCY 17.0B
- IPO Year
- CSL N/A
- INCY 1993
- Fundamental
- Price
- CSL $320.00
- INCY $106.35
- Analyst Decision
- CSL Buy
- INCY Buy
- Analyst Count
- CSL 6
- INCY 20
- Target Price
- CSL $386.67
- INCY $90.71
- AVG Volume (30 Days)
- CSL 533.1K
- INCY 2.4M
- Earning Date
- CSL 10-29-2025
- INCY 10-28-2025
- Dividend Yield
- CSL 1.39%
- INCY N/A
- EPS Growth
- CSL N/A
- INCY 3878.02
- EPS
- CSL 17.56
- INCY 5.90
- Revenue
- CSL $5,015,100,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- CSL $1.17
- INCY $19.33
- Revenue Next Year
- CSL $2.98
- INCY $10.47
- P/E Ratio
- CSL $18.06
- INCY $17.90
- Revenue Growth
- CSL 0.14
- INCY 18.09
- 52 Week Low
- CSL $293.43
- INCY $53.56
- 52 Week High
- CSL $466.86
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- CSL 51.54
- INCY 66.97
- Support Level
- CSL $293.43
- INCY $100.30
- Resistance Level
- CSL $314.23
- INCY $107.61
- Average True Range (ATR)
- CSL 9.92
- INCY 2.97
- MACD
- CSL 1.27
- INCY -0.48
- Stochastic Oscillator
- CSL 80.38
- INCY 67.35
About CSL Carlisle Companies Incorporated
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.